All In Biotech

NDA 019481 · United Guardian

Renacidin

Citric Acid, Gluconolactone, Magnesium Carbonate · Irrigation · Calculi Dissolution Agent; Anti-coagulant

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Dec 16, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Oct 2, 1990

Approved uses

1

Original approval plus efficacy supplements

Registered trials

516

148 Phase 3, 44 recruiting

FAERS reports

17

14 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 17, 2019.

INDICATIONS AND USAGE Renacidin is indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy tube as an alternative or adjunct to surgical procedures. Renacidin is also indicated for use as an intermittent irrigating solution to prevent encrustations of indwelling urethral catheters and cystostomy tubes.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 2, 1990 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • RENACIDIN · CITRIC ACID 6.602GM/100ML; GLUCONOLACTONE 198MG/100ML; MAGNESIUM CARBONATE 3.177GM/100ML · SOLUTION, IRRIGATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Citric Acid" as an intervention, any sponsor and status, largest first.

All 516 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cardio-respiratory arrest2
  • device failure2
  • fall2
  • haematuria2
  • nephrolithiasis2
  • septic shock2
  • urinary tract infection2
  • acute respiratory distress syndrome1
  • apnoea1
  • aspiration1
  • asthenia1
  • balance disorder1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20082
20101
20121
20131
20141
20163
20173
20202
20231
20241
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Renacidin (Citric Ac/Gluconolact/Mag Carb)

2024 spending

$2.5M

Beneficiaries

2,447

11,498 claims

Per beneficiary

$1,034

$0.21 per unit

View as table
YearSpending
2020$2,830,933
2021$2,845,825
2022$2,806,041
2023$3,028,080
2024$2,530,320

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 506 on PubMed

Sponsor: United Guardian

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.